Revised treatment and testing guidelines for latent tuberculosis infection.
D000293:Adolescent; D000995:Antitubercular Agents / Q000627:therapeutic use; D002487:Centers for Disease Control and Prevention, U.S.; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D012307:Risk Factors; D012955:Societies, Medical; D014376:Tuberculosis / Q000175:diagnosis / Q000628:therapy; D014481:United States
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin